Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

Kuo-Tung Tang; Tsu-Yi Hsieh; Ya-Hsuan Chao; Meng-Xian Lin; Yi-Hsing Chen; Der-Yuan Chen; Chi-Chen Lin

doi:10.1371/journal.pone.0178404

Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

PLoS One. 2017 May 30;12(5):e0178404. doi: 10.1371/journal.pone.0178404. eCollection 2017.

Authors

Kuo-Tung Tang^{1

2}, Tsu-Yi Hsieh¹, Ya-Hsuan Chao³, Meng-Xian Lin³, Yi-Hsing Chen^{1

4}, Der-Yuan Chen^{1

3

4

5

6}, Chi-Chen Lin³

Affiliations

¹ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, R.O.C.
² Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, R.O.C.
³ Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, R.O.C.
⁴ School of Medicine, National Yang-Ming University, Taipei, R.O.C.
⁵ Department of Medical Research, Taichung Veterans General Hospital, Taichung, R.O.C.
⁶ Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, R.O.C.

Abstract

Introduction: Many studies have demonstrated elevated circulating levels of high-mobility group box 1 (HMGB1) and decreased circulating levels of soluble receptor for advanced glycation end products (sRAGE) in patients with autoimmune diseases. In the present study, we investigated plasma levels of both HMGB1 and sRAGE in primary antiphospholipid syndrome (pAPS) patients.

Methods: We prospectively recruited 11 pAPS patients, 17 antiphospholipid antibody (APA)-positive SLE patients without APS manifestations (APA+SLE) and 12 SLE patients with secondary APS (APS+SLE). We also recruited 10 healthy controls (HCs). Plasma levels of HMGB1 and sRAGE were determined using sandwich ELISA kits. In addition, plasma levels of HMGB1 were also determined using Western blot in 6 pAPS patients and 6 HCs.

Results: There was no significant difference in plasma levels of HMGB1 measured by ELISA among subgroups of the enrolled subjects. In addition, there was no significant difference in plasma levels of HMGB1 measured by Western blot between pAPS patients and HCs. On the other hand, we observed a trend toward lower plasma levels of sRAGE in APA+SLE or APS+SLE patients when compared with HCs. However, there was no significant difference in plasma levels of sRAGE between pAPS patients and HCs, or between APA+SLE patients and APS+SLE patients.

Conclusion: There was no significant difference in plasma levels of sRAGE or HMGB1 between pAPS patients and HCs. Plasma levels of sRAGE/HMGB1 could not be utilized to differentiate between APA+SLE and APS+SLE patients.

MeSH terms

Adult
Antiphospholipid Syndrome / blood*
Blotting, Western
Enzyme-Linked Immunosorbent Assay
Female
HMGB1 Protein / blood*
Humans
Male
Middle Aged
Receptor for Advanced Glycation End Products / blood*

Substances

HMGB1 Protein
Receptor for Advanced Glycation End Products

Grants and funding

This work was supported by grants from the Taichung Veterans General Hospital and National Chung Hsing University (TCVGH-NCHU1047611), Taichung, Taiwan, Republic of China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.